Background
Inherited genetic variation may impact patient response and risk of toxicity following immune checkpoint inhibitor (ICI) therapy.
Methods
We conducted an agnostic genome-wide analysis study for inherited genetic variants that may predict t…
Background
This study evaluated biomarker profiles associated with therapeutic response and prognosis in resectable non-small cell lung cancer (NSCLC) receiving neoadjuvant camrelizumab plus chemotherapy.
Methods
In this single-arm phase II trial, pa…
Background
Radiopharmaceutical therapy (RPT) delivers radiation systemically, enabling the treatment of metastatic cancers. Beyond killing tumor cells, RPT can modulate the tumor immune microenvironment. With RPTs and immunotherapies already approved …
Background
Immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs) share symptomatic and therapeutic similarities with chronic inflammatory diseases (CIDs). However, the molecular distinctions between irAEs and CIDs remain…
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. However, ICIs are associated with potentially life-threatening immune-related adverse events (irAEs). Janus kinase inhibitors (JAKi) are a promising steroid-sparing agent…
Background
Cytokine release syndrome (CRS) is a life-threatening toxicity of chimeric antigen receptor T-cell therapy (CART) for B-cell acute lymphoblastic leukemia (B-ALL). Lower rates of severe CRS have been reported in patients treated with CD22-di…
Ovarian cancer (OC) remains one of the deadliest gynecologic malignancies, and, despite the presence of tumor-infiltrating lymphocytes (TILs) in nearly half of cases, immune checkpoint inhibitors have shown only modest clinical benefit. These observat…
Background
As a key downstream effector of the Hippo signaling pathway, Yes-associated protein (YAP) has emerged as a pivotal regulator of tumor immune evasion and resistance to immune checkpoint inhibitors (ICIs). However, the relationship between YA…
Cancer immunotherapy, particularly immune checkpoint blockade (ICB), has represented a major advancement for the treatment of various cancers. Though ICB has been an effective tool in the clinical management of patients, a significant subset of indivi…
Background
This first-in-human clinical study explored lomvastomig, an immunoglobulin G1-based Fc-silenced bispecific antibody that simultaneously blocks the immune checkpoint receptors programmed cell death protein 1 (PD-1) and T-cell immunoglobulin …
